SCHEMBL1857877

SCHEMBL1857877

NCCCn1cc(Br)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.36
PKM P14618 2/20 0.34
MAPT P10636 1/20 0.34
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
PIM1 P11309 1/20 0.31
CSNK2A2 P19784 1/20 0.31
CSNK2B P67870 1/20 0.31
CSNK2A1 P68400 1/20 0.31
CSNK2A3 Q8NEV1 1/20 0.31
POLB P06746 1/20 0.31
PLAU P00749 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16065410 0.92 ALDH1A1 (0.40) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL17406960 0.92 ALDH1A1 (0.40) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL3321065 0.88
Hydrochloric Acid SCHEMBL1854633 0.86 ALDH1A1 (0.43) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL31049315 0.80 ALDH1A1 (0.42) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL2029566 0.80 ALDH1A1 (0.42) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL672494 0.80 ALDH1A1 (0.42) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL15421298 0.79
SCHEMBL16065232 0.78 ALDH1A1 (0.41) ALDH1A1KMT2AHSD17B10TSHRMAPK1
SCHEMBL1228571 0.78 ALDH1A1 (0.41) ALDH1A1KMT2AHSD17B10TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA ALDH1A1 2279/4885KMT2A 2966/4885HSD17B10 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.